Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:55:59 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CADL - CANDEL THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CADL - Q0.16.00·6.900.16.39-0.04-0.6389.22,3991,4396.51  6.60  6.0211.3999  0.6619:59:37Apr 2515 min RT 2¢

Recent Trades - Last 10 of 1439
Time ETExPriceChangeVolume
19:59:37Q6.560.13200
18:52:21Q6.49830.06835
18:49:09Q6.500.074
18:09:57Q6.37-0.0610
17:33:16Q6.37-0.06400
17:29:09Q6.37-0.0697
17:13:28Q6.37-0.06274
17:12:36Q6.500.07183
16:57:00Q6.500.0717
16:18:41Q6.500.07160

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 08:00U:CADLNews ReleaseCandel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
2024-04-11 09:00U:CADLNews ReleaseCandel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
2024-04-09 08:00U:CADLNews ReleaseCandel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
2024-04-04 08:00U:CADLNews ReleaseCandel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2024-03-28 16:05U:CADLNews ReleaseCandel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
2024-03-28 08:06U:CADLNews ReleaseCandel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
2024-03-05 16:30U:CADLNews ReleaseCandel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
2024-02-13 07:30U:CADLNews ReleaseCAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
2024-02-05 08:00U:CADLNews ReleaseCandel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
2023-12-12 08:00U:CADLNews ReleaseCandel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
2023-11-28 09:00U:CADLNews ReleaseCandel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN ¢ „ ¢ Discovery Platform, and Key Clinical Readouts for CAN-2409
2023-11-09 08:00U:CADLNews ReleaseCandel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-04 08:00U:CADLNews ReleaseCandel Therapeutics Presents Preclinical Data from its enLIGHTEN ¢ „ ¢ Discovery Platform at SITC
2023-11-03 12:00U:CADLNews ReleaseCandel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2023-10-18 11:00U:CADLNews ReleaseCandel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
2023-09-27 09:41U:CADLNews ReleaseCandel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
2023-09-26 08:00U:CADLNews ReleaseCandel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
2023-09-06 08:00U:CADLNews ReleaseCandel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 08:00U:CADLNews ReleaseCandel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-02 08:00U:CADLNews ReleaseCandel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference